Using advanced imaging to detect and monitor pancreatic cancer
Official title: Precision Imaging for Early Detection and Targeted Treatment Monitoring in Pancreatic Cancer
Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT06144762 · Data updated 2026-11-12
This study is testing a new way to use advanced MRI images to better spot and track pancreatic cancer in patients, helping doctors catch it earlier and manage treatment more effectively.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Montpellier) |
| Status | Recruiting |
| Started | December 19, 2023 |
| Main results expected | October 2029 |
| Study ends | October 2029 |
| Registry record updated | February 12, 2025 |
| Trial ID | NCT06144762 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with pathologically proven pancreatic cancer who are eligible for surgery or neoadjuvant chemotherapy.
✕Probably not a fit
Patients with metastatic pancreatic cancer or those who will not undergo surgery are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project aims to develop a model that captures tumor heterogeneity in pancreatic cancer using a multiscale radiomics approach. By obtaining both in vivo and ex vivo MRI images, the study seeks to create a virtual histology representation of tumors, which can be applied to routine clinical MRI for early detection and treatment monitoring. The goal is to provide a comprehensive, non-invasive characterization of pancreatic cancer, addressing the challenges of early diagnosis and effective treatment. This innovative approach could significantly enhance patient management and outcomes.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and better monitoring of pancreatic cancer, ultimately improving patient survival rates.
How similar studies have gone: While the approach of using radiomics for cancer detection is gaining traction, this specific application in pancreatic cancer is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged \>18 2. * Pathologically proven pancreatic cancer which can beneficiate of upfront surgery or delayed surgery followed by neoadjuvant chemotherapy. * Negative pregnancy test for women of childbearing potential * Patients affiliated to a social protection system * Written informed consent signed before project onset. Exclusion Criteria: * presence of metastases, * Patient who will not have surgery * Pregnant or breastfeeding women * Mental or psychological state, physical or legal incapacity preventing participation in the project.
Where it's running
-
NOUGARET Stephanie
Montpellier, France Recruiting
Study contacts
- Study coordinator: MOUSSION Aurore
- Email: aurore.moussion@icm.unicancer.fr
- Phone: 0467613102
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
INSPIRE: Putting patient-reported info into multidisciplinary tumor boards
This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.
-
MRI scan for detecting pancreatic cancer in people at high risk
This study tests a dedicated pancreas MRI (MRP) tool to see if it helps find pancreatic cancer earlier in people with a strong family or genetic risk.
-
Cutting down ultra-processed foods for people at high cancer risk
This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.
-
Carbon nanoparticle‑loaded iron for advanced solid tumors
This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.
-
Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids
This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.